Tellus Therapeutics

Tellus Therapeutics is a private, early-stage biotech founded with a mission to address critical, unmet medical needs in neonatal care, specifically brain and gut injuries in premature infants. The company's lead candidate, TT-20, is a pioneering myelination therapy targeting neonatal white matter injury, representing a novel regenerative medicine approach. Tellus is building a platform based on breakthrough discoveries in neonatology and is actively engaged in the North Carolina life sciences ecosystem, presenting at investor events like Triangle Venture Day. The company's strategy is to start where the need is greatest—the NICU—and expand its technology to broader neuro-regenerative applications.

A regenerative medicine platform focused on promoting myelination to repair brain injury, initially developed for neonatal white matter injury with potential expansion to other demyelinating and inflammatory diseases.

Total raised: $3.5M

The neonatal white matter injury space has no approved disease-modifying therapies, making Tellus a potential pioneer. Competition may come from academic groups exploring neuroprotection and large pharma eventually entering the space. Tellus's differentiation is its specific focus on myelination as a regenerative endpoint.